Please ensure Javascript is enabled for purposes of website accessibility
top of page

Antisense oligonucleotide silencing of FUS expression as a therapeutic approach in amyotrophic later

Vladislav A. Korobeynikov, Alexander K. Lyashchenko, Beatriz Blanco-Redondo, Paymaan Jafar-Nejad & Neil A. Shneider (Nature Medicine)


Fused in sarcoma (FUS) is an RNA-binding protein that is genetically and pathologically associated with rare and aggressive forms of amyotrophic lateral sclerosis (ALS) and frontotemporal dementia (FTD). To explore the mechanisms by which mutant FUS causes neurodegeneration in ALS-FTD, we generated a series of FUS knock-in mouse lines that express the equivalent of ALS-associated mutant FUSP525L and FUSΔEX14 protein. In FUS mutant mice, we show progressive, age-dependent motor neuron loss as a consequence of a dose-dependent gain of toxic function, associated with the insolubility of FUS and related RNA-binding proteins.



Korobeynikov, V.A., Lyashchenko, A.K., Blanco-Redondo, B. et al. Antisense oligonucleotide silencing of FUS expression as a therapeutic approach in amyotrophic lateral sclerosis. Nat Med 28, 104–116 (2022). https://doi.org/10.1038/s41591-021-01615-z

18 views
bottom of page